epitope of the target polypeptide and a second binding moiety which specifically binds a matrix, to thereby provide a reaction mixture;

contacting the reaction mixture with a matrix which specifically binds the second binding moiety of the multivalent binding polypeptide; [and]

removing reaction mixture which does not bind to the matrix, to thereby obtain the target polypeptide from the product[.] ; and

wherein the reaction mixture is substantially fluid.

6. The method according to claim 5, further comprising eluting the target polypeptide from the matrix.

8. The method according to claim 5, wherein the target polypeptide is an antibody.

9. (Twice Amended) The method according to claim 8, wherein the first binding moiety of the transgenic multivalent binding polypeptide is protein L or a chemically functional fragment thereof.

10. (Twice Amended) The method according to claim 9, wherein the second binding moiety of the transgenic multivalent binding polypeptide is a cellulose bind domain (CBD) or a chemically functional fragment thereof.

12. (Twice Amended) A method of obtaining a target polypeptide having a bindable epitope from the milk of a first non-human transgenic mammal, the method comprising:

contacting milk which comprises a target polypeptide having a bindable epitope with a transgenically produced multivalent binding polypeptide, wherein the multivalent binding polypeptide comprises a first binding moiety which specifically binds the bindable epitope of the target polypeptide and a second binding moiety which specifically binds a matrix, to thereby provide a reaction mixture;

contacting the reaction mixture with a matrix which specifically binds the second binding moiety of the multivalent binding polypeptide; [and]

removing reaction mixture which does not bind to the matrix, to thereby obtain the target polypeptide from the milk[.] ;

wherein the reaction mixture is substantially fluid; and,

wherein the transgenically produced multivalent binding polypeptide is produced in milk from a second non-human transgenic mammal.

13. The method according to claim 12, further comprising eluting the target polypeptide from the matrix.

14. The method of claim 12, wherein the target polypeptide is a transgenically produced polypeptide.

PLEASE CANCEL CLAIM 15

19. The system according to claim 2, wherein the transgenically produced multivalent polypeptide further comprises a third binding moiety and the third binding moiety is capable of removing the bindable epitope from the target polypeptide.

20. The method according to claim *5,* wherein the transgenically produced multivalent polypeptide further comprises a third binding moiety and the third binding moiety is capable of removing the bindable epitope from the target polypeptide.

21. The method of claim 5, wherein the first binding moiety of the multivalent binding polypeptide is an antibody or functional fragment thereof which binds the bindable epitope of the target polypeptide.

22. (Amended) The method of claim 5, wherein the second binding moiety of the multivalent binding polypeptide is a cellulose binding domain (CBD), or a chemically functional fragment thereof.

23. The method of claim 5, wherein the target polypeptide is a receptor and the first binding moiety of the multivalent binding polypeptide is a ligand which binds the bindable epitope of the receptor.

24. The method of claim 5, wherein the first binding moiety of the multivalent binding polypeptide is a receptor which binds the bindable epitope of the target polypeptide.

25. The method according to claim 12, wherein the transgenically produced multivalent binding polypeptide is produced in the milk of [the] a second non-human transgenic mammal.

26. The method of claim 12, wherein the transgenically produced multivalent polypeptide further comprises a third binding moiety and the third binding moiety is capable of removing the bindable epitope from the target polypeptide.

27. (Amended) The method of claim 12, wherein the first binding moiety of the multivalent binding polypeptide is an antibody or chemically functional fragment thereof which binds the bindable epitope of the target polypeptide.

28. (Amended) The method of claim 12, wherein the second binding moiety of the multivalent binding polypeptide is a cellulose binding domain (CBD), or a chemically functional fragment thereof.

29. The method of claim 12, wherein the target polypeptide is a receptor and the first binding moiety of the multivalent binding polypeptide is a ligand which binds the bindable epitope of the receptor.

30. The method of claim 12, wherein the first binding moiety of the multivalent binding polypeptide is a receptor which binds the bindable epitope of the target polypeptide.

Please add claims 31-36